In this review, a systematic literature search was performed and the evidence on the cost effectiveness of conventional chemotherapy and targeted therapy for metastatic breast cancer was explored.
Cost-effectiveness/-utility analysis of treatment regimens for metastatic breast cancer were identified using literature and reference searches (MED-LINE). Published reports on conventional and targeted cancer therapies were scrutinized and incremental cost-effectiveness ratios (ICERs) were abstracted. Furthermore, the quality of reporting, as well as methodological and modeling issues, were extensively discussed.
From full-text article reviews, six cost-effectiveness analyses on conventional therapies and seven studies on targeted therapies were included. Eight analyses were conducted in European countries, three in the US and two in Canada. The economic models were primarily (69%) based on clinical trial data. Results from sensitivity analyses and study perspectives were reported by all studies. Discount rates were mentioned in five articles (39%). The methods of reporting costs and effects varied considerably, as did trial design across conventional chemotherapies, which made it difficult to compare those analyses.
The pharmacoeconomic studies came to different conclusions. The actual clinical evidence does not suggest one conventional chemotherapy regimen as superior. Studies on cytotoxic agents showed mainly favourable costeffectiveness ratios. Targeted therapies indicated both favourable and nonfavourable ratios. Currently, trastuzumab is the only antibody-based targeted therapy that is established in the clinic for the metastatic setting.
Breast cancer is the most common cancer diagnosed in women in Western countries. About 25-40% of breast cancer patients develop a metastasis in the course of their illness. [1, 2] Since metastatic breast cancer (MBC) is not curable, one of the main goals of treating patients is to provide palliation of symptoms and the maintenance or improvement of quality of life (QOL). The prolongation of life expectancy is a secondary goal. The armamentarium for palliative treatment contains potent endocrine treatments for the hormone receptor-positive breast cancers, bisphosphonates for the subset of patients with bone disease, targeted therapy for, so far, mainly the subgroup of HER2 (human epidermal growth factor receptor 2)-positive patients and, finally, conventional cytotoxic chemotherapy.
Conventional chemotherapeutics do not act on the diverse signalling pathways that help the tumour progress, but rather target dividing cells in general and are therefore associated with a wide range of adverse effects. For breast cancer, in particular, conventional chemotherapy for metastatic disease is usually administered after the failure of endocrine treatment. A high percentage of patients with early breast cancer receive adjuvant combination chemotherapy, which affects the choice of the regimen administered for MBC. Patients with breast cancer recurring after having received anthracyclines in the adjuvant setting usually receive a taxane-containing regimen, whereas patients who have received adjuvant taxanes usually receive an anthracycline-based regimen. [3] Targeted drugs exploit specific molecular characteristics of the tumour and do not usually affect cells without that specific target. Several classes of antibody-based targeted therapies have raised hope in the treatment of breast cancer. [4] Trastuzumab (Herceptin Ò , Roche Pharma, Switzerland), a monoclonal antibody targeted to the HER2 receptor is currently routinely used in both the early breast cancer and metastatic settings for patients with HER2-positive tumours. [5] The efficacy and safety of trastuzumab as firstline treatment in MBC has been demonstrated in several randomized controlled trials. [6] [7] [8] [9] However, trastuzumab is limited to 15-25% of breast cancer patients overexpressing the HER2 receptor or amplifying the HER2 oncogene. [10] [11] [12] Lapatinib is an orally available dual tyrosine kinase inhibitor of the HER2 kinase and has been approved in some countries for HER2 MBC progressing under trastuzumab treatment or as first-line oral treatment in combination with endocrine therapy. [13] Pertuzumab, a further monoclonal antibody that binds a different epitope on HER2 from trastuzumab is under clinical assessment. This agent has been developed for breast cancer patients, whether overexpressing HER2 or not. [14, 15] Bevacizumab (Avastin Ò , Roche Pharma, Switzerland) is a monoclonal antibody directed against vascular endothelial growth factor-A. Given its antiangiogenic properties, it is being evaluated in the metastatic setting, and is showing promising results. [16] Bevacizumab has been approved in a combination therapy for MBC with a negative HER2 status. [17] The complex economics of new oncology drug developments are an important area of research. [18] However, progress in the development of new cancer treatments is connected to costs, namely treatment-related expenses and effects on QOL. Particularly expensive drugs must demonstrate relevant improvements in regard to length of life, QOL or if there is no alternative available to be regarded as justified. [19, 20] In response to the growing concern about the costs of pharmaceutical products, pharmacoeconomic studies investigate the impact of new drugs or interventions on the patient's QOL and the healthcare outcome through, for example, cost-effectiveness studies. Economic analyses ideally cover clinical and economic outcomes achieved in randomized controlled trials. Such models play an important role in policy makers' decisions regarding coverage and reimbursement of products.
The aim of this review was to compare and summarize findings of published, original costeffectiveness analyses of chemotherapy and targeted non-chemotherapy regimens for MBC that presented results as cost-per-life-year gained (LYG) or QALY. The quality of reporting was critically assessed. Particular emphasis was placed on the key drivers of cost effectiveness of the various treatment agents.
Literature Review

Data Source and Selection
MEDLINE and PubMed were searched systematically for all original cost-effectiveness analyses published between 2000 and 2009. Given that the field of targeted therapies is new, we included studies published only from the year 2000 onwards to ensure a comparable study population in both conventional and targeted therapeutic settings. The search included the following keywords: 'cost', 'effectiveness', 'utility', 'breast', 'cancer metastatic' and 'advanced'. A total of 671 articles were recognized in the initial literature search. Titles and abstracts were screened by two independent reviewers (KJD, PRB) to determine whether the reports were an original health economic study. The full text of studies considered important after the first screening cycle were evaluated. For literature saturation, reference lists were explored for relevant reports. Studies were included if they were reports on cost effectiveness, or cost-utility reports of MBC therapies. Descriptive cost studies, posters, editorials, publications not showing primary data or reports in languages other than English were excluded. Cost-effectiveness analyses primarily describing the health economic impact of hormonal therapies or predictive testing in targeted non-chemotherapy settings were not taken into account. Figure 1 outlines how the final sample size was reached.
Detailed information from the reports was abstracted using a pre-specified checklist. A standardized extraction form was used to gather the following issues from the studies: (i) characteristics of the study (study design, population, perspective); (ii) type and outcome of the economic analysis; and (iii) key aspects (cancer treatment and comparator strategy, clinical outcome, costs and discount rate) and parameters of the sensitivity analysis (if available). For the base-case analysis, incremental cost-effectiveness ratios (ICERs) were reported. Studies were grouped into cost-effectiveness analyses addressing either conventional chemotherapy or targeted regimens. Particular emphasis on the key drivers of cost effectiveness of the various chemotherapy and targeted regimens was given. As year of reference, the reported monetary year or the year of publication was used. Costs are shown in $US (h1 D $US1.47; d1 D $US1.74; $Can1 D $US1).
Overview of Included Papers
Included studies focused on breast cancer patients in MBC. Outcome measures were given in either QALYs (7 of 13) or in LYG (6 of 13). Eight analyses were conducted in European countries (France, Greek, Norway, Switzerland, UK), three in the US and two in Canada. Only one article was published in a pharmacoeconomic and outcome research journal, [21] whereas the remaining articles were published in oncology or public health journals. The funding source was mentioned in nine studies (69%).
The methodologies used varied considerably. The studies all used model-based analyses for their calculations. Three articles [21] [22] [23] mentioned that Markov models had been established, whereas only two clearly described the methodological approach of the model. The remaining studies used other economic models. Data included were derived primarily from randomized controlled trial data (9 of 13). Two studies [24, 25] were based on cancer registry and medical record information, respectively. One study [26] was conducted with data from an open, controlled, prospective study and one article [27] included data from published literature. The studies were simulated from a healthcare payer (10 of 13), a hospital (1 of 13) or a societal (2 of 13) perspective. A discount rate of 3% (3 of 13), 3.5% (1 of 13) or 5% (1 of 13) was applied. The discount rates were largely applied to both costs and outcomes. The remaining studies did not state discount rates. In the sensitivity analyses performed, mainly costs and clinical effect variables were varied. The economic analyses based on conventional chemotherapies were all considered cost effective by the authors, except one study with ixabepilone. [28] In the studies of targeted regimens, authors concluded that the monoclonal antibody treatment was cost effective (3 of 7), [25, 26, 29] not cost effective (3 of 7) [22, 23, 27] or gave no clear statement (1 of 7). [30] The summary of cost-effectiveness results of conventional and targeted regimens is given in tables I and II, respectively.
Cost Effectiveness of Conventional Chemotherapies
Maniadakis et al. [32] analysed the cost effectiveness of three taxane-based regimens that are [31] Maniadakis et al. [32] Reed et al. [33] Vu et al. [34] Benedict et al. [35] Verma and Ilersich [36] Year [31] Maniadakis et al. [32] Reed et al. [33] Vu et al. [34] Benedict et al. [35] Verma and Ilersich [36] Incremental cost ($US) Cap + Doc is cost effective Cap = capecitabine; Cb = carboplatin; Doc = docetaxel; G = gemcitabine; ICER = incremental cost-effectiveness ratio; Ixb = ixabepilone; LYG = life-years gained; nabPac = nanoparticle albumin-bound paclitaxel; NS = not stated; Pac = paclitaxel; PF = progression-free; RCT = randomized controlled trial; 1w = once weekly; 3w = every 3 weeks. Norum et al. [37] Perez-Ellis et al. [25] Poncet et al. [38] Hornberger et al. [29] Garrison and Veenstra [39] Dedes et al. [40] Le and Hay [41] Year Norum et al. [37] Perez-Ellis et al. [25] Poncet et al. [38] Hornberger et al. [29] Garrison and Veenstra [39] Dedes et al. [40] Le and Hay [41] Discount rate (%) A = anthracycline; AC = anthracycline + cyclophosphamide; BEV = bevacizumab; C = capecitabine; CL = confidence limits; Doc = docetaxel; Epi = epirubicine; HER2+ = human epidermal growth factor receptor 2 positive; ICER = incremental cost-effectiveness ratio; L = lapatinib; LYG = life-year gained; max. = maximum; MBC = metastatic breast cancer; MoH = Ministry of Health; NS = not stated; OS = overall survival; Pac = paclitaxel; Pacw = paclitaxel weekly; pt = patient; QALM = quality-adjusted life-month; RCT = randomized controlled trial; SC = standard chemotherapy; T = trastuzumab; Tax = taxane; WTP = willingness to pay.
administered as first-line chemotherapy in patients with MBC who have already received anthracyclines in the adjuvant setting. This economic analysis, conducted from the perspective of the Greek national health system, was based on the randomized phase III trial [42] comparing carboplatin (area under the curve [AUC] of 6) and paclitaxel (175 mg/m 2 administered every 3 weeks for six cycles) versus paclitaxel weekly (80 mg/m 2 weekly for 12 weeks) or docetaxel 75 mg/m 2 plus gemcitabine 1000 mg/m 2 every 3 weeks. [43] The paclitaxel weekly arm appeared to be the most preferable choice among the three regimens as it prolonged overall survival (OS) more than the other combinations without being associated with higher adverse effects. The QOL was similar in all three arms. Docetaxel with gemcitabine incurred the lowest total costs per patient (h19 343; $US28 434) but proved to be less effective than the two paclitaxel-containing regimens and caused more severe myelotoxicity and mucositis. Paclitaxel with carboplatin every 3 weeks cost about the same amount per patient as paclitaxel weekly (h20 498 vs h20 578; $US30 132 vs $US30 250) but was significantly less effective. These results remained fairly constant in sensitivity analyses.
Vu et al. [34] compared the cost effectiveness of docetaxel 100 mg/m 2 versus paclitaxel 175 mg/m 2 , both administered every 3 weeks. The analysis was conducted from the perspective of the Canadian healthcare system. The clinical data, in contrast to many other cost-effectiveness studies, was not based on a clinical trial but was derived from a provincial cancer registry. The OS in the docetaxel-treated group was significantly higher than among patients treated with paclitaxel (10.9 vs 8.3 months). This benefit was similar to the results of a randomized trial comparing both agents. [44] The costs per patient were substantially higher in the docetaxel group ($Can9441 vs $Can2944; $US9441 vs $US2944), which was attributed to the higher acquisition costs of docetaxel. The ICER was $Can30 337 ($US30 337) per LYG for docetaxel versus paclitaxel.
Benedict et al. [35] compared the same regimens for the UK healthcare system as Vu et al. [34] but used clinical data from a randomized controlled trial. [45, 46] In contrast to Vu et al., [34] Benedict et al. [35] included QOL data retrieved from the literature. Furthermore, the authors indirectly included two additional regimens (paclitaxel weekly and nab-paclitaxel 1 every 3 weeks) by including data from other randomized controlled trials. However, for paclitaxel weekly, evidence from two abstracts from meeting proceedings was used rather than the best available evidence. [48] In the model, the hazard ratios of docetaxel, paclitaxel weekly and nab-paclitaxel every 3 weeks were applied to the baseline hazard with paclitaxel every 3 weeks to model the progressionfree and OS curves. The proportion of patients in each of the three health states (no progression, progression, death) was calculated at each time point for each treatment.
The relative difference between the mean costs per patient in the docetaxel 3-weekly group versus the paclitaxel 3-weekly group was smaller than in the population-based analysis for Canada. [34] Furthermore, the clinical benefit derived from a randomized clinical trial was higher than in the Canadian study, proving that data from randomized controlled trials are not always reproducible in clinical practice. The ICER was found to be d4583-14 694 ($US7974-25 567) per QALY for docetaxel 3-weekly compared with paclitaxel 3-weekly, weekly and nab-paclitaxel, which is regarded as acceptable for the UK healthcare system. Verma and Ilersich [36] compared the costs and outcomes of oral daily capecitabine 2500 mg/m 2 plus 3-weekly docetaxel 75 mg/m 2 with 3-weekly docetaxel 100 mg/m 2 from the perspective of the Canadian healthcare system by combining data from a randomized controlled trial [49] with a population-based model. The randomized clinical trial showed a survival benefit of 3 months (14.5 vs 11.5 months) for the combination treatment. Combination treatment was accompanied with an increase in grade 3 adverse events (71% vs 49%), whereas the monotherapy arm showed a slightly higher rate of grade 4 events (31% vs 25%). The ICER for the combination treatment was $Can3691 ($US3691) per LYG. Unfortunately, this analysis did not account for QOL.
The efficacy and safety of nab-paclitaxel in the first-and second-line treatment of MBC were demonstrated in a large randomized trial with paclitaxel serving as the control arm. In that study, nab-paclitaxel was statistically superior to paclitaxel in terms of objective tumour (33% vs 19%; p = 0.001) and progression-free survival (PFS) [23 vs 16.9 weeks; p = 0.006]. [50] There was also a trend in favour of nab-paclitaxel in OS, but it did not reach statistical significance (median 65.0 vs 55.7 weeks; p = 0.37). Patients randomized to the nab-paclitaxel arm had a lower incidence of neutropenia but higher grades of sensory neuropathy. In another trial, different dosages of nabpaclitaxel were compared with the other taxane, docetaxel. The trial compared two dosages for weekly administration (100 and 150 mg/m 2 ) and an every 3 week (300 mg/m 2 ) schedule of nabpaclitaxel versus docetaxel. [50] Nab-paclitaxel 150 mg/m 2 weekly demonstrated significantly longer PFS than docetaxel by both independent radiologist assessment (12.9 vs 7.5 months, respectively; p = 0.0065) and investigator assessment (14.6 vs 7.8 months, respectively; p = 0.012). Based on these data, which included only PFS data and no OS data, Dranitsaris et al. [31] conducted an economic evaluation from the perspective of the UK healthcare system. Nab-paclitaxel 150 mg/m 2 weekly was associated with the highest cost per patient (d27 222; $US47 366) due to the acquisition cost and costs for supportive care (growth factors, blood transfusions, antibacterials and antiemetics). The docetaxel arm was the less expensive treatment arm, with d12 923 ($US22 486) mean cost per patient. The incremental 5.4 progression-free months gained by nab-paclitaxel 150 mg/m 2 compared with docetaxel resulted in a ratio of d31 800 ($US55 332) per progression-free year gained. QOL was not considered in this costeffectiveness analysis. The authors concluded that nab-paclitaxel can be considered a reasonable alternative to docetaxel as first-line chemotherapy for MBC and, if considering the favourable adverse effect profile of nab-paclitaxel, the inclusion of QOL and utility benefits would further improve its economic profile.
Finally, Reed et al. [33] analysed the cost effectiveness from the perspective of the US healthcare system of adding ixabepilone to capecitabine as third-line chemotherapy after progression under anthracyclines and taxanes. The results of this study should be cautiously compared with all previously mentioned cost-effectiveness analyses, as the underlying patient population had experienced recurrence or progression despite treatments with anthracyclines and taxanes, which is associated with poorer response to any chemotherapy and poorer survival expectation as such. Clinical data were extracted from a randomized controlled trial, [51, 52] from which QOL results were also available and incorporated. The addition of ixabepilone prolonged OS by 32 quality-adjusted days. The incremental costs for the combination therapy amounted to around $US30 000, which resulted in an ICER of $US359 000 per QALY. The authors concluded that this ratio is higher than for other new treatments in MBC.
Cost Effectiveness of Targeted Therapies
Norum et al. [37] described a model-based costeffectiveness analysis of trastuzumab in MBC patients that included data on efficacy, tolerability, gain in survival and drug costs from a third-party payer perspective. Based on data presented at breast cancer conferences [53, 54] and a MEDLINE search, they assessed LYG and associated costs in patients treated with standard chemotherapy (docetaxel, anthracycline plus cyclophosphamide or paclitaxel) compared with the addition of intravenous (IV) trastuzumab 4 mg/kg (initial dose) and 2 mg/kg (weekly dose). Direct costs included drug costs, the assessment of HER2 status, and hospitalization and outpatient clinic costs. Costs for the chemotherapeutic agents were assumed to be similar between treatment arms so they were not incorporated in the model. No indirect costs were included. The incremental survival time with trastuzumab was between 0.3 and 0.7 years compared with standard chemotherapy. Drug costs (89% of overall costs) and the prolonged treatment in the outpatient clinic (8% of overall costs) were the key factors driving costs in the trastuzumab group. Depending on survival gain and discount rate applied, incremental cost effectiveness ranged from h69 212 to h162 417 ($US101 742 to $US238 753) per LYG. Drug costs and survival time significantly influenced the base-case results in sensitivity analyses. The authors concluded that the costs of administering trastuzumab to patients with MBC for the gain of 1 year of life were considerable.
The cost-effectiveness study of trastuzumab published by Perez-Ellis et al. [25] was based on a retrospective analysis of medical files and associated cost data of HER2-positive patients treated for first metastatic progression. Trastuzumab administration was given as a single agent or in combination with chemotherapy (taxanes). Treatment with trastuzumab was limited to 1 year or until disease progression (standard schedule IV 4 mg/kg [initial dose], IV 2 mg/kg [weekly dose]). Control patients received standard treatment (taxanes-and/or anthracycline-based chemotherapy). Treatment costs were based on hospital direct costs (inpatient hospitalization stay, drug costs, imagery test, etc). Costs for predictive testing of HER2 status were omitted from the analysis. Data on QOL were not considered. In terms of OS, the trastuzumab group showed superior results (37 months vs 19 months in the nontrastuzumab group; p < 0.001). The per-patient costs in the trastuzumab group were considerably higher than in the non-trastuzumab group (h39 607 [$US58 222] vs h12 795 [$US18 809], respectively). The main cost drivers were the price of trastuzumab (40% of the total costs in the trastuzumab group) and the length of hospitalization (60% of total costs in the no-trastuzumab group). Of note, hospital room costs and the number of imagery tests were substantially higher in the trastuzumab group. The ICER assessed by the bootstrapping method was considered cost effective (h27 492 [$US40 413] per LYG). Bivariate sensitivity analysis was performed under several assumptions in regard to trastuzumab unit costs (-25%, -50%, -75%) and hospitalization costs (-50%). The associated ICER ranged from h8000 ($US11 760) to h20 000 ($US29 400) per LYG.
In an open, controlled, prospective study, Poncet et al. [38] evaluated the costs and effects for patients receiving a combination therapy of IV trastuzumab (3-weekly schedule of 4 mg/kg [initial dose], 2 mg/kg [maintenance dose]) and paclitaxel (trastuzumab + paclitaxel) or control therapy (any chemotherapy without trastuzumab). According to the medical files of those patients, all costs generated from the hospital were included in the analysis (overall care costs, drug costs, immunohistochemical tumour analysis, hospital stay, etc.). Effectiveness was assessed in terms of OS and PFS. The 1-year OS rate showed a significant difference between comparator and control group (0.85 vs 0.47, respectively; p = 0.007). The difference in 1-year PFS was not statistically significant (60% vs 42%, respectively). The mean ICER was h15 370 ($US22 594) per LYG for trastuzumab. Poncet et al. [38] concluded that the strategy of adding trastuzumab to paclitaxel therapy seems to be affordable from the perspective of the French healthcare system. To obtain equivalent mean cost effectiveness in both groups, the threshold analysis evaluated that the costs of a trastuzumab flask would need to be h432 ($US635) instead of the h626 ($US920) paid in 2002.
Hornberger et al. [29] assessed the cost effectiveness of first-line trastuzumab treatment of MBC HER2-positive patients (trastuzumab + paclitaxel vs paclitaxel). Trastuzumab was administed once weekly (4mg/kg loading dose, 2 mg/kg maintenance dose). [55] Patients with progressing cancer were allowed to receive trastuzumab as secondline treatment (75% in paclitaxel group, 47% in trastuzumab + paclitaxel group). Data on response duration and OS were derived from a randomized controlled study (n = 469). [7] The model comprised the costs of chemotherapy; the rate, severity and costs of adverse events; and QOL. Clinical benefits were measured in achieved prolonged survival and improved quality-adjusted life-months (QALMs). The combined therapy arm achieved a survival mean of 25.0 months compared with 15.2 months in the paclitaxel arm. In addition to this, the trastuzumab + paclitaxel treatment gained higher QALMs than the control group (12.3 vs 6.4 QALM, respectively), but also increased healthcare costs by d18 330 ($US31 894). However, the corresponding ICER was assumed to be cost effective (d37 500 [$US65 250] per QALY) and upon the recommendation of the UK National Institute for Health and Clinical Excellence (NICE) Appraisal Committee, treatment of MBC with trastuzumab + paclitaxel was regarded as justified.
The majority of pharmacoeconomic studies include only one specific indication. Garrison and Veenstra [39] established a dynamic life-cycle model to evaluate the use of trastuzumab in multiple indications (adjuvant and MBC with a HER2-positive expression pattern) to estimate the overall economic value of the agent. Based on publicly available data, QALYs and direct treatment costs were estimated for the product lifecycle of trastuzumab over 18 years. The authors aimed to forecast the volume of use of trastuzumab (given with paclitaxel) over the product lifecycle as well as estimating its cost effectiveness (vs paclitaxel alone) across early-stage and MBC patients from a payer perspective in the US. The model included costs for HER2 testing (immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH] ), trastuzumab therapy until disease progression, and supervising and treating adverse events. The cost assumptions of trastuzumab treatment in MBC patients were based on current medication costs, survival estimates and utility weights derived from published studies. The authors projected the number of patients treated with trastuzumab as three times lower in MBC than in the adjuvant setting. Accordingly, 161 000 women with MBC would be treated during the entire modelling period. The volume of trastuzumab use and associated costs resulted in an indication-specific ICER of $US85 676 per QALY gained for MBC. The ICER for the overall life-cycle summed to $US35 590 per QALY (ICER for early breast cancer $US26 417 per QALY).
One article examined the health economic outcome of lapatinib in HER2-overexpressing MBC patients. [41] The life-long Markov model comprised information on clinical effectiveness from results of two randomized controlled trials of lapatinib (EGF100151, [56] EGF20002 [57] ). Published literature was used to gather information on health-state utilities, direct and indirect costs of the therapy, primary adverse events, laboratory tests and costs of disease progression. The model took the US societal perspective. Adding lapatinib to capecitabine therapy yielded additional costs of $US19 630 and 0.12 QALYs. The corresponding ICER resulted in $US166 113 per QALY gained. The sensitivity analyses revealed a lower probability of 2% to reach an ICER below $US150 000 per QALY. Hence, the willingnessto-pay (WTP) threshold is most probably not reachable.
The only cost-effectiveness study on bevacizumab in the first-line treatment of MBC was published by Dedes et al. [40] The study group analysed the economic outcomes of bevacizumab plus paclitaxel versus paclitaxel monotherapy in HER2-negative MBC patients. Study design and data on PFS and OS were based on a randomized clinical trial. [16] With the help of a Markov model, cost effectiveness (expressed as costs per QALY) was assessed. Cost data covered direct costs of chemotherapy treatment, most important adverse events, laboratory tests and disease progression. No indirect costs were taken into account. Utilities were derived from published literature. The combined therapy of paclitaxel + bevacizumab summed to additional per-patient costs of h40 369 in combination with a gain of 0.21 QALYs. Consequentially, the ICER summed to h189 427 ($US278 458) per QALY. The subgroup analysis showed an increasing ICER with age. Due to an improved benefit in efficacy, the ICER of the younger population (aged 27-49 years, ICER h152 823 [$US224 650] per QALY) was considerably lower than that of the older population (aged 65-85 years, ICER h1 226 615 [$US1 803 124] per QALY). The impact of statistical uncertainties around the main input variables were assessed by one-way and probabilistic sensitivity analyses. By varying time to progression (-50%) in the paclitaxel + bevacizumab group, this treatment strategy became dominated. The variation of time (-50%) from progression to death (paclitaxel arm) showed a further considerable influence in sensitivity analysis. In conclusion, the authors believe that MBC treatment with bevacizumab plus paclitaxel is high and above the generally accepted cost-effectiveness threshold of h60 000 ($US88 200) per QALY gained.
Quality Assessment of Key Modelling Issues
Several factors may have an influence on the cost-effectiveness ratio, including funding source, input parameters, under-reporting and the quality of the data integrated in the model.
Input Parameters
It is of paramount importance to include reliable input parameters in a model. Some articles [25, 27, 31] mentioned in their study limitations the problem of including data from a small trial sample size. A few articles [21, 27] were based on data from abstracts, which is probably not the best source of reliable information. Several trials [21, 22, 28, 58] were powered to show significant results in regard to clinical response or PFS, but not in terms of OS. Hence, those trials may identify significant improvements in primary endpoints, but the gains in survival remain non-significant. Conducting cost-effectiveness analyses based on such results are justified, so long as probabilistic sensitivity analyses are performed to assess the impact of model assumptions not principally related to statistical uncertainties.
Sensitivity Analyses
Sensitivity analyses are usually carried out in order to estimate the influence of the statistical uncertainties around the model inputs. All analyses included in this review performed sensitivity analyses, but there were major differences in their quality. Most studies conducted deterministic sensitivity analyses to assess the robustness of the base case by varying variables with a direct impact on incremental cost within a certain range (e.g. -30%). Clearly described probabilistic sensitivity analyses were found in three articles. [21] [22] [23] One article [25] used the bootstrapping concept, which differs from probabilistic sensitivity analyses by drawing observations from a data set rather than taking random points in a distribution. However, several studies [26, 29, 58] did not mention how the sensitivity analyses were performed or what parameters had been used. The robustness of the study results can only be shown if sensitivity analyses have taken all variables into account, especially those with a potential impact on the cost-effectiveness ratio. Critical components in a sensitivity analysis are prices and quantities, functional relationships, the health-related QOL measure and discount rates.
Perspective of the Analysis
Most studies took the health system perspective (77%). These analyses do not take into account indirect costs, although improved cancer survival enhances the overall social surplus (improved labour force potential). However, a huge percentage of breast cancer patients are of working age. Given this, indirect cost savings and gains in productivity could potentially be considerable and should not be disregarded. Only two articles [22, 59] took the societal perspective, in which not only direct and non-direct medical costs but also indirect costs were included.
Influences on the Cost-Effectiveness Ratio
As shown in this review, the cost effectiveness of trastuzumab was mainly influenced by the drug cost of trastuzumab, outpatient costs and administration costs. The expenditures for administration can be influenced by switching from a weekly administration interval to a 3-weekly schedule. However, the cost-effectiveness ratio identified by Norum et al. [37] did not significantly improve with the 3-weekly interval when compared with the weekly interval. From the patient's point of view, a 3-weekly schedule may yield an enhancement in QOL. However, the weekly administration of trastuzumab has been shown to be superior compared with the 3-weekly course in terms of median PFS (13.4 months vs 8.8 months, respectively). [60] Among conventional chemotherapies, only nab-paclitaxel was studied for different administration schedules. Weekly administration of nab-paclitaxel was associated with more total costs per patient than 3-weekly administration but the improved clinical benefit for the weekly schedule offset these costs. [31] The acquisition cost was found to be a further influential variable. [37, 38] In one analysis, lowering the cost of a trastuzumab flask by about h200 ($US294) meant the mean costs per LYG would equal that achieved with conventional chemotherapy. [38] The standard unit of trastuzumab is a 150 mg vial. It could be argued that providing different sized vials (10 mg, 50 mg) could lower the costs by administering only the exact drug dosage needed.
In addition, the duration of treatment with trastuzumab seems to be a point of discussion. The duration scheme of the targeted therapy in the included studies ranged between 24 weeks (eight cycles) [38] and 1 year [25] or until disease progression. [25, 38, 39] Prolonging treatment would be associated with increased per-patient costs.
[61]
Comparability of Different Studies
Typically, thresholds for cost-effectiveness ratios for a novel healthcare intervention range from $US50 000 per QALY in the US to d30 000 ($US52 200) per QALY in UK. [62] Although these thresholds are generally regarded as acceptable, the true societal WTP for a new intervention is unknown. It might be reasonable to amend this threshold across higher-and lower-income countries. [63] The included analyses have been conducted in the US/Canada (38%) or Europe (62%). The limitation of comparing studies from various countries lies not only in striking differences in the cost and resources included. There are different approaches and factors that have to be considered when using model-based costeffectiveness analyses across different geographic regions. [64] For the adjuvant treatment with trastuzumab, Essers et al. [65] presented a possibility of transferring a model-based economic study by assessing criteria and limitations of transferability. However, the main challenge to transferring and comparing results from different studies is mainly the transparency of the methods. Given that several studies [29, 32, 34, 36] did not clearly mention how the economic model was performed (states, cycle length, software used), it is very difficult to compare the model results. Hence, one major problem in evaluating the quality of costeffectiveness analyses is under-reporting.
Role of Funding
Several analyses were conducted using funding from pharmaceutical companies that market the analysed drugs. [29, 33, 35, 39, 66] Some others did not declare conflicts of interest or funding and had no author affiliated with a pharmaceutical company. [25, 32, 34, 37, 38, 40, 41] Although pharmaceutical company sponsorship has not been found to bias individual health economic studies, it has been reported that it is associated with reduced likelihood of reporting unfavourable results. [67] This suggests that pharmaceutical-sponsored studies are less likely to publish negative results. In fact, among the economic analyses reviewed in this article that reported negative or borderline results regarding cost-effectiveness ratios, all but one [28] were conducted and published by independent research groups. [37, 40, 41] 
Discussion
In recent years, many studies addressing the issue of cost and effectiveness of various new regimens for MBC have been published. Developments in the understanding of the molecular pathology of breast cancer have enabled the use of targeted therapies for adjuvant and MBC. At the forefront of development among conventional chemotherapies, potentially more potent drugs (docetaxel, ixabepilone) or established drugs with improved drug delivery formulations (nab-paclitaxel) have entered clinical trials and are successfully used in daily clinical practice. Therapies to target specific cellular pathways expand effective cancer drugs by allowing systematic patient selection. However, the introduction of new drugs for cancer therapy usually increases treatment costs. Pharmacoeconomic analyses are in great demand in order to obtain a better understanding of the cost-benefit ratio of promising cancer drugs.
Among the new conventional chemotherapy regimens, there are some striking differences in trial design and included patient populations that makes comparisons across the different costeffectiveness studies difficult. The role of anthracyclines for the adjuvant and metastatic (if not received adjuvantly) treatment of most of the breast cancer types is still not refutable. This is one of the main reasons that most cost-effectiveness analyses focus on second-line therapy after either metastatic or adjuvant anthracycline-containing regimens. At progression or recurrence after anthracyclines, a taxane-containing regimen offers the best response rates and is considered the standard of care. [3] Despite several phase III studies conducted so far, there is still no agreement on the best taxane-containing regimen for second-line chemotherapy. Docetaxel has been shown to be superior to 3-weekly paclitaxel, [44] but a separate trial suggested that weekly paclitaxel is more effective than 3-weekly paclitaxel. [48] On the other hand, docetaxel every week is inferior to 3-weekly docetaxel. [68] Furthermore, nab-paclitaxel has been compared with docetaxel in a phase II trial and showed superiority. [50] While phase II trials are not perfect venues to compare agents, docetaxel was outperformed with regard to overall response rate by nabpaclitaxel in this setting. Similarly, the head-tohead comparison of nab-paclitaxel with standard paclitaxel was a comparison employing 3-weekly paclitaxel and not the more effective weekly regimen. [69] At present, it seems reasonable to consider all three agents useful for MBC, but it is difficult to declare a 'best' agent on objective grounds. Therefore, cost-effectiveness studies should not omit one of the above three regimens. Unfortunately, weekly paclitaxel has been included as a comparator in only two cost-effectiveness studies, [21, 58] and results from one study suggested it was not only the most efficient regimen but also the most cost effective. [32] If economic studies are conducted with poor clinical trial data, poor outcomes will result. There is an ongoing debate over whether costeffectiveness analyses should only be conducted if the difference in clinical effectiveness between two treatment strategies is statistically significant. [70] [71] [72] However, if such data are used in economic studies, adequate sensitivity analyses have to be carried out to evaluate if those input parameters have an influence on the base-case result. Recently, Chan et al. [73] published a review on cost-effectiveness analyses of trastuzumab in the adjuvant setting. The authors concluded that trastuzumab seems to be cost effective in this setting; nevertheless, they suggested further highquality economic studies with clinical data showing the efficacy of trastuzumab in clinical practice were necessary.
Adjuvant treatment with targeted therapies may reduce the future incidence of MBC. In our review, we did not include any articles that assessed the impact of adjuvant trastuzumab treatment on the reduced drug usage in the future metastatic indication in those patients. [74] From a health economic point of view, the adjuvant and metastatic setting should be evaluated separately, since these are two separate decisions. If lifetime incidence projections make a distinction between newly and previously diagnosed MBC, bias may occur due to epidemiological double counting, which leads to the overestimation of costs and effects of the cancer therapy. [39] On the other hand, most cost-effectiveness studies are based on clinical data of patients naive to the evaluated targeted drug; however, developments in clinical practice are also shifting the usage of targeted therapies to adjuvant therapy. For example, in the case of trastuzumab, the patient population on which Norum et al. [37] based their costeffectiveness analysis are now virtually non-existent since literally all of them receive trastuzumab in the adjuvant setting. If these patients develop metastases, it is not clear to what extent they will benefit from the same targeted treatment nor which targeted treatment is the most appropriate. Since many new targeted treatments are gaining market approval for various indications in breast cancer and some are also starting to be administered adjuvantly (such as trastuzumab and probably soon lapatinib), cost-effectiveness studies for MBC, according to our review, often do not keep pace with new clinical developments.
Generally, the ICER of targeted non-chemotherapeutics is higher than that of conventional chemotherapeutics. Given different comparators and treatment regimens, the lifetime ICER for trastuzumab varied considerably. The economic models showed some major differences in their approach to assessing the cost effectiveness of targeted therapies. The economic model used was clearly described in only a few articles. [22, 23] The two publications [22, 23] focusing on bevacizumab and lapatinib, respectively, showed no favourable ICER. Those two studies were based on clinical trial results and clearly described the model methodology, the parameters included and the analyses performed. Furthermore, the authors did not receive any funding from the pharmaceutical industry.
Cost-effectiveness thresholds vary between countries. Usually, threshold values of $US20 000, $US50 000 or $US100 000 per QALY or LYG are applied. [75] In the metastatic setting, several studies on antibody-based targeted therapies indicated an unfavourable ICER. [37, 40, 41] In spite of this, trastuzumab has been established in clinical practice in both the adjuvant and metastatic setting.
There are some limitations to this systematic review. The review excluded articles written in languages other than English. Furthermore, results presented at meetings (abstracts) were not included. In addition, the search was limited to the database and the keywords described, which may have omitted some cost-effectiveness analyses.
Cost-effectiveness analyses on new therapies for MBC are rarely found in the published literature and high-quality economic models are needed. For agents such as bevacizumab or nabpaclitaxel, the clinical benefit in terms of OS is still under investigation and it remains to be seen if these new therapies will be established in clinical practice as routine therapies.
Conclusions
We conducted a systematic review of costeffectiveness studies of chemotherapy and targeted regimens for MBC. In this setting, only a few studies were found with varying conclusions. Studies on cytotoxic agents showed mostly favourable cost-effectiveness ratios, while those on targeted therapies showed both favourable and non-favourable ratios. The cost-effectiveness ratio seems to be dependent on the drug price, the extent of improvement in survival rates, and the administration schedule. However, the interpretation of cost-effectiveness studies should not only be limited to the value of the ICER achieved. The quality of the data and the key modelling parameters included in the analysis should be considered. However, in the case of trastuzumab, the patient population included in the costeffectiveness analyses no longer reflects HER2-positive MBC patients, as almost all current patients will have already received trastuzumab adjuvantly. Many healthcare systems will have problems with accepting the high cost-effectiveness ratios of some expensive cancer treatments. Trastuzumab, for example, is widely justified due to its clinical benefit. Pharmacoeconomic decisions about the management of new agents such as bevacizumab or nab-paclitaxel will appear as soon as enough clinical evidence is available.
